



GP 1806

#29
B. Denny
10/22/96

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Application of:

Cindy A. Jacobs and Craig A. Smith

Docket No. 2503-A

Group Art Unit: 1806

Examiner: John Lucas

Serial No.: 08/385,229

Filing Date: February 8, 1995

For: METHODS OF LOWERING ACTIVE TNF- α LEVELS IN
MAMMALS USING TUMOR NECROSIS FACTOR RECEPTOR
(AS AMENDED)Commissioner Of Patent and
Trademarks
Washington, DC 20231

Attention: Group Director

**PETITION FOR CONSIDERATION OF INFORMATION
DISCLOSURE STATEMENT**

Applicants Petition for the consideration of the attached Information Disclosure Statement which is mailed after the mailing of the Notice of Allowance in connection with the above identified application. Applicants authorize the Commissioner to charge applicants deposit account no. 09-0089 for the Petition fee under 37 CFR 1.17(i)(1) in the amount of \$130.00. Applicants authorize the charging of any additional amount to the same account if it is determined additional fees are necessary to properly consider this Petition.

Respectfully submitted,


Stephen L. Malaska
Registration No. 32,655Law Department
Immunex Corporation
51 University Street
Seattle, WA 98101
(206) 587-0430**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Date: 8/29/96Signed: Nancy M. Sinton

MG11006 09/09/96 08385229

09-0089 110 122

130.00CH

RECEIVED
ALLOWED FILES/COPIES
PUBLISHED IN USPTO
96 OCT 10 PM 2:13
96 SEP 17 PM 1:10
GROUP 100



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Cindy A. Jacobs and Craig A. Smith

Docket No. 2503-A

Group Art Unit: 1806

Serial No.: 08/385,229

Examiner: John Lucas


Filing Date: February 8, 1995

For: METHODS OF LOWERING ACTIVE TNF- α LEVELS IN
MAMMALS USING TUMOR NECROSIS FACTOR RECEPTOR
(AS AMENDED)

CERTIFICATION UNDER 37 CFR 1.97(e)

I certify according to 37 CFR 1.97(e)(2) that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application or, to my knowledge after making a reasonable inquiry, was known to any individual designated in 37 CFR 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,



Stephen L. Malaska
Registration No. 32,655

Law Department
Immunex Corporation
51 University Street
Seattle, WA 98101
(206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Date: 8/29/96

Signed: James M. Kerton



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Cindy A. Jacobs and Craig A. Smith

Docket No. 2503-A

Group Art Unit: 1806

Serial No.: 08/385,229

Examiner: John Lucas

Filing Date: February 8, 1995

For: METHODS OF LOWERING ACTIVE TNF- α LEVELS IN
MAMMALS USING TUMOR NECROSIS FACTOR RECEPTOR
(AS AMENDED)


**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AFTER THE
MAILING OF THE NOTICE OF ALLOWANCE**

Pursuant to the provisions of 37 CFR §§1.56, 1.97 and 1.98, applicants hereby provide a copy of the following document which also is listed on the attached Form PTO-1449.

US Patent No. 5,512,544 -Wallach, et. al.; "Pharmaceutical Compositions Comprising an Anticytokine."

Because this Information Disclosure Statement is being mailed after the mailing of the Notice of Allowance, applicants also submit a Petition requesting consideration of this Information Disclosure Statement, a certification under 37 CFR 1.97(e), and the Petition fee under 37 CFR 1.17(i)(1).

Respectfully submitted,



Stephen L. Malaska
Registration No. 32,655

Law Department
Immunex Corporation
51 University Street
Seattle, WA 98101
(206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Date: 8/29/96

Signed: Glancey M. Katoen